Made in China: TaiMed wins FDA OK for a 'breakthrough' HIV therapy for drug-resistant patients
The FDA has handed TaiMed and its partners at Theratechnologies an approval for the first new HIV drug to come along in a decade with a novel mechanism of action.
The drug, to be marketed as Trogarzo (ibalizumab-uiyk), works by binding to the second extracellular domain of the CD4+ T cell receptor, away from other binding sites used by drugs already on the market. That approach allows patients who are becoming resistant to their therapies to add this to the mix before being exposed to a lethal amount of virus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.